Tom Wei-Wu Chen, MD, National Taiwan University Hospital, Taipei, Taiwan, talks on the next steps for the Phase I/II LEADER trial (NCT03526679), including a potential randomised clinical trial, to continue investigation of lenvatinib plus eribulin for patients with liposarcoma and leiomyosarcoma. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.